2 0 1 0 1 B-lower_bound
or 2 4 2 4 O
more 5 9 5 9 O
new 10 13 10 13 O
lesions 14 21 14 21 O
on 22 24 22 24 O
bone 25 29 25 29 B-treatment
scan 30 34 30 34 I-treatment

Active 0 6 35 41 O
psychiatric 7 18 42 53 B-chronic_disease
illness 19 26 54 61 I-chronic_disease
/ 26 27 61 62 I-chronic_disease
social 27 33 62 68 I-chronic_disease
situations 34 44 69 79 I-chronic_disease
that 45 49 80 84 O
would 50 55 85 90 O
limit 56 61 91 96 O
compliance 62 72 97 107 O
with 73 77 108 112 O
protocol 78 86 113 121 O
requirements 87 99 122 134 O

Any 0 3 135 138 O
other 4 9 139 144 O
radiotherapy 10 22 145 157 B-treatment
or 23 25 158 160 O
radionuclide 26 38 161 173 B-treatment
require 39 46 174 181 O
28 47 49 182 184 O
- 49 50 184 185 O
day 50 53 185 188 O
washout 54 61 189 196 O
prior 62 67 197 202 O
to 68 70 203 205 O
first 71 76 206 211 O
dose 77 81 212 216 O
of 82 84 217 219 O
study 85 90 220 225 B-treatment
drug 91 95 226 230 I-treatment

Any 0 3 231 234 O
prior 4 9 235 240 B-treatment
therapy 10 17 241 248 I-treatment
for 18 21 249 252 O
castrate 22 30 253 261 O
disease 31 38 262 269 O
is 39 41 270 272 O
acceptable 42 52 273 283 O
except 53 59 284 290 O
prior 60 65 291 296 B-treatment
specific 66 74 297 305 I-treatment
cytochrome 75 85 306 316 I-treatment
P450 86 90 317 321 I-treatment
family 91 97 322 328 I-treatment
17 98 100 329 331 I-treatment
( 101 102 332 333 I-treatment
CYP17 102 107 333 338 I-treatment
) 107 108 338 339 I-treatment
antagonists 109 120 340 351 I-treatment
( 121 122 352 353 O
e.g. 122 126 353 357 O
abiraterone 127 138 358 369 B-treatment
acetate 139 146 370 377 I-treatment
, 146 147 377 378 O
orteronel 148 157 379 388 B-treatment
) 157 158 388 389 O
or 159 161 390 392 O
prior 162 167 393 398 B-treatment
second 168 174 399 405 I-treatment
generation 175 185 406 416 I-treatment
AR 186 188 417 419 I-treatment
antagonists 189 200 420 431 I-treatment
( 201 202 432 433 O
e.g. 202 206 433 437 O
enzalutamide 207 219 438 450 B-treatment
or 220 222 451 453 O
ARN509 223 229 454 460 B-treatment
) 229 230 460 461 O
which 231 236 462 467 O
are 237 240 468 471 O
excluded 241 249 472 480 O
other 250 255 481 486 O
than 256 260 487 491 O
enzalutamide 261 273 492 504 O
as 274 276 505 507 O
specified 277 286 508 517 O
for 287 290 518 521 O
phase 291 296 522 527 O
II 297 299 528 530 O
portion 300 307 531 538 O

Aspartate 0 9 539 548 B-clinical_variable
aminotransferase 10 26 549 565 I-clinical_variable
( 27 28 566 567 I-clinical_variable
AST 28 31 567 570 I-clinical_variable
) 31 32 570 571 I-clinical_variable
( 33 34 572 573 O
serum 34 39 573 578 B-clinical_variable
glutamic 40 48 579 587 I-clinical_variable
oxaloacetic 49 60 588 599 I-clinical_variable
transaminase 61 73 600 612 I-clinical_variable
[ 74 75 613 614 I-clinical_variable
SGOT])/alanine 75 89 614 628 I-clinical_variable
aminotransferase 90 106 629 645 I-clinical_variable
( 107 108 646 647 I-clinical_variable
ALT 108 111 647 650 I-clinical_variable
) 111 112 650 651 I-clinical_variable
( 113 114 652 653 O
serum 114 119 653 658 B-clinical_variable
glutamate 120 129 659 668 I-clinical_variable
pyruvate 130 138 669 677 I-clinical_variable
transaminase 139 151 678 690 I-clinical_variable
[ 152 153 691 692 I-clinical_variable
SGPT 153 157 692 696 I-clinical_variable
] 157 158 696 697 I-clinical_variable
) 158 159 697 698 O
= 160 161 699 700 O
< 161 162 700 701 O
2.5 163 166 702 705 B-upper_bound
x 167 168 706 707 I-upper_bound
institutional 169 182 708 721 I-upper_bound
upper 183 188 722 727 I-upper_bound
limit 189 194 728 733 I-upper_bound
of 195 197 734 736 I-upper_bound
normal 198 204 737 743 I-upper_bound

Blood 0 5 744 749 B-clinical_variable
pressure 6 14 750 758 I-clinical_variable
that 15 19 759 763 O
is 20 22 764 766 O
not 23 26 767 770 O
controlled 27 37 771 781 O
despite 38 45 782 789 O
> 46 47 790 791 O
2 48 49 792 793 B-lower_bound
oral 50 54 794 798 O
agents 55 61 799 805 O
( 62 63 806 807 O
systolic 63 71 807 815 B-clinical_variable
blood 72 77 816 821 I-clinical_variable
pressure 78 86 822 830 I-clinical_variable
[ 87 88 831 832 I-clinical_variable
SBP 88 91 832 835 I-clinical_variable
] 91 92 835 836 I-clinical_variable
> 93 94 837 838 O
160 95 98 839 842 B-lower_bound
and 99 102 843 846 O
diastolic 103 112 847 856 B-clinical_variable
blood 113 118 857 862 I-clinical_variable
pressure 119 127 863 871 I-clinical_variable
[ 128 129 872 873 I-clinical_variable
DBP 129 132 873 876 I-clinical_variable
] 132 133 876 877 I-clinical_variable
> 134 135 878 879 O
90 136 138 880 882 B-lower_bound
documented 139 149 883 893 O
during 150 156 894 900 O
the 157 160 901 904 O
screening 161 170 905 914 O
period 171 177 915 921 O
with 178 182 922 926 O
no 183 185 927 929 O
subsequent 186 196 930 940 B-clinical_variable
blood 197 202 941 946 I-clinical_variable
pressure 203 211 947 955 I-clinical_variable
readings 212 220 956 964 O
< 221 222 965 966 O
160/100 223 230 967 974 B-upper_bound
) 230 231 974 975 O

Concurrent 0 10 976 986 B-treatment
therapy 11 18 987 994 I-treatment
with 19 23 995 999 I-treatment
strong 24 30 1000 1006 I-treatment
inhibitors 31 41 1007 1017 I-treatment
or 42 44 1018 1020 O
inducers 45 53 1021 1029 O
of 54 56 1030 1032 O
cytochrome 57 67 1033 1043 B-treatment
P450 68 72 1044 1048 I-treatment
family 73 79 1049 1055 I-treatment
3 80 81 1056 1057 I-treatment
, 81 82 1057 1058 O
subfamily 83 92 1059 1068 B-treatment
A 93 94 1069 1070 I-treatment
, 94 95 1070 1071 O
polypeptide 96 107 1072 1083 B-treatment
4 108 109 1084 1085 I-treatment
( 110 111 1086 1087 I-treatment
CYP3A4 111 117 1087 1093 I-treatment
) 117 118 1093 1094 I-treatment
or 119 121 1095 1097 O
cytochrome 122 132 1098 1108 B-treatment
P450 133 137 1109 1113 I-treatment
family 138 144 1114 1120 I-treatment
2 145 146 1121 1122 I-treatment
, 146 147 1122 1123 O
subfamily 148 157 1124 1133 B-treatment
C 158 159 1134 1135 I-treatment
, 159 160 1135 1136 O
polypeptide 161 172 1137 1148 B-treatment
8 173 174 1149 1150 I-treatment
( 175 176 1151 1152 I-treatment
CYP2C8 176 182 1152 1158 I-treatment
) 182 183 1158 1159 I-treatment
due 184 187 1160 1163 O
to 188 190 1164 1166 O
concerning 191 201 1167 1177 O
possible 202 210 1178 1186 O
drug 211 215 1187 1191 O
- 215 216 1191 1192 O
drug 216 220 1192 1196 O
interactions 221 233 1197 1209 O

Corrected 0 9 1210 1219 O
QT 10 12 1220 1222 B-clinical_variable
interval 13 21 1223 1231 I-clinical_variable
( 22 23 1232 1233 I-clinical_variable
QTc 23 26 1233 1236 I-clinical_variable
) 26 27 1236 1237 I-clinical_variable
on 28 30 1238 1240 O
electrocardiogram 31 48 1241 1258 B-clinical_variable
( 49 50 1259 1260 I-clinical_variable
EKG 50 53 1260 1263 I-clinical_variable
) 53 54 1263 1264 I-clinical_variable
> 55 56 1265 1266 O
450 57 60 1267 1270 B-lower_bound
msec 61 65 1271 1275 I-lower_bound

Denosumab 0 9 1276 1285 B-chronic_disease
or 10 12 1286 1288 O
zoledronic 13 23 1289 1299 B-chronic_disease
acid 24 28 1300 1304 I-chronic_disease

Eastern 0 7 1305 1312 B-clinical_variable
Cooperative 8 19 1313 1324 I-clinical_variable
Oncology 20 28 1325 1333 I-clinical_variable
Group 29 34 1334 1339 I-clinical_variable
( 35 36 1340 1341 I-clinical_variable
ECOG 36 40 1341 1345 I-clinical_variable
) 40 41 1345 1346 I-clinical_variable
performance 42 53 1347 1358 I-clinical_variable
status 54 60 1359 1365 I-clinical_variable
= 61 62 1366 1367 O
< 62 63 1367 1368 O
2 64 65 1369 1370 B-upper_bound

Evidence 0 8 1371 1379 O
of 9 11 1380 1382 O
castrate 12 20 1383 1391 B-clinical_variable
testosterone 21 33 1392 1404 I-clinical_variable
level 34 39 1405 1410 I-clinical_variable
< 40 41 1411 1412 O
50 42 44 1413 1415 B-upper_bound
ng 45 47 1416 1418 I-upper_bound
/ 47 48 1418 1419 I-upper_bound
dL 48 50 1419 1421 I-upper_bound
( 51 52 1422 1423 O
or 52 54 1423 1425 O
surgical 55 63 1426 1434 O
castration 64 74 1435 1445 O
) 74 75 1445 1446 O

Histologically 0 14 1447 1461 O
or 15 17 1462 1464 O
cytologically 18 31 1465 1478 O
confirmed 32 41 1479 1488 O
prostate 42 50 1489 1497 B-cancer
cancer 51 57 1498 1504 I-cancer

History 0 7 1505 1512 O
of 8 10 1513 1515 O
other 11 16 1516 1521 O
malignancies 17 29 1522 1534 B-cancer

History 0 7 1535 1542 O
of 8 10 1543 1545 O
seizure 11 18 1546 1553 B-chronic_disease
disorder 19 27 1554 1562 I-chronic_disease
or 28 30 1563 1565 O
active 31 37 1566 1572 O
use 38 41 1573 1576 O
of 42 44 1577 1579 O
anticonvulsants 45 60 1580 1595 B-treatment

Inability 0 9 1596 1605 O
to 10 12 1606 1608 O
swallow 13 20 1609 1616 O
capsules 21 29 1617 1625 O
or 30 32 1626 1628 O
known 33 38 1629 1634 O
gastrointestinal 39 55 1635 1651 O
malabsorption 56 69 1652 1665 B-chronic_disease

Lack 0 4 1666 1670 O
of 5 7 1671 1673 O
radiographic 8 20 1674 1686 O
progression 21 32 1687 1698 O
as 33 35 1699 1701 O
defined 36 43 1702 1709 O
by 44 46 1710 1712 O
Response 47 55 1713 1721 O
Evaluation 56 66 1722 1732 O
Criteria 67 75 1733 1741 O
in 76 78 1742 1744 O
Solid 79 84 1745 1750 O
Tumors 85 91 1751 1757 O
( 92 93 1758 1759 O
RECIST 93 99 1759 1765 O
) 99 100 1765 1766 O
1.1 101 104 1767 1770 O
and 105 108 1771 1774 O
Prostate 109 117 1775 1783 B-cancer
Cancer 118 124 1784 1790 I-cancer
Working 125 132 1791 1798 O
Group 133 138 1799 1804 O
Criteria 139 147 1805 1813 O

New 0 3 1814 1817 B-clinical_variable
York 4 8 1818 1822 I-clinical_variable
Heart 9 14 1823 1828 I-clinical_variable
Association 15 26 1829 1840 I-clinical_variable
( 27 28 1841 1842 I-clinical_variable
NYHA 28 32 1842 1846 I-clinical_variable
) 32 33 1846 1847 I-clinical_variable
class 34 39 1848 1853 B-lower_bound
II 40 42 1854 1856 I-lower_bound
, 42 43 1856 1857 O
NYHA 44 48 1858 1862 O
class 49 54 1863 1868 O
III 55 58 1869 1872 O
, 58 59 1872 1873 O
or 60 62 1874 1876 O
IV 63 65 1877 1879 B-upper_bound
congestive 66 76 1880 1890 B-chronic_disease
heart 77 82 1891 1896 I-chronic_disease
failure 83 90 1897 1904 I-chronic_disease
( 91 92 1905 1906 O
any 92 95 1906 1909 O
symptomatic 96 107 1910 1921 B-chronic_disease
heart 108 113 1922 1927 I-chronic_disease
failure 114 121 1928 1935 I-chronic_disease
) 121 122 1935 1936 O

PSA 0 3 1937 1940 B-clinical_variable
= 4 5 1941 1942 O
< 5 6 1942 1943 O
1.25 6 10 1943 1947 B-upper_bound
times 11 16 1948 1953 I-upper_bound
the 17 20 1954 1957 O
PSA 21 24 1958 1961 O
at 25 27 1962 1964 O
start 28 33 1965 1970 O
of 34 36 1971 1973 O
enzalutamide 37 49 1974 1986 B-treatment

PSA 0 3 1987 1990 B-clinical_variable
evidence 4 12 1991 1999 O
for 13 16 2000 2003 O
progressive 17 28 2004 2015 O
prostate 29 37 2016 2024 B-cancer
cancer 38 44 2025 2031 I-cancer
consists 45 53 2032 2040 O
of 54 56 2041 2043 O
a 57 58 2044 2045 O
minimum 59 66 2046 2053 O
PSA 67 70 2054 2057 B-clinical_variable
level 71 76 2058 2063 I-clinical_variable
of 77 79 2064 2066 O
at 80 82 2067 2069 O
least 83 88 2070 2075 O
2 89 90 2076 2077 B-lower_bound
ng 91 93 2078 2080 I-lower_bound
/ 93 94 2080 2081 I-lower_bound
ml 94 96 2081 2083 I-lower_bound
, 96 97 2083 2084 O
which 98 103 2085 2090 O
has 104 107 2091 2094 O
subsequently 108 120 2095 2107 O
risen 121 126 2108 2113 O
on 127 129 2114 2116 O
at 130 132 2117 2119 O
least 133 138 2120 2125 O
2 139 140 2126 2127 O
successive 141 151 2128 2138 O
occasions 152 161 2139 2148 O
, 161 162 2148 2149 O
at 163 165 2150 2152 O
least 166 171 2153 2158 O
2 172 173 2159 2160 B-lower_bound
weeks 174 179 2161 2166 I-lower_bound
apart 180 185 2167 2172 O

Progressive 0 11 2173 2184 B-chronic_disease
disease 12 19 2185 2192 I-chronic_disease
on 20 22 2193 2195 O
computed 23 31 2196 2204 B-treatment
tomography 32 42 2205 2215 I-treatment
( 43 44 2216 2217 I-treatment
CT)/magnetic 44 56 2217 2229 I-treatment
resonance 57 66 2230 2239 I-treatment
imaging 67 74 2240 2247 I-treatment
( 75 76 2248 2249 I-treatment
MRI 76 79 2249 2252 I-treatment
) 79 80 2252 2253 I-treatment
according 81 90 2254 2263 O
to 91 93 2264 2266 O
Response 94 102 2267 2275 O
Evaluation 103 113 2276 2286 O
Criteria 114 122 2287 2295 O
in 123 125 2296 2298 O
Solid 126 131 2299 2304 O
Tumors 132 138 2305 2311 O
( 139 140 2312 2313 O
RECIST 140 146 2313 2319 O
) 146 147 2319 2320 O
1.1 148 151 2321 2324 O
criteria 152 160 2325 2333 O

Record 0 6 2334 2340 O
of 7 9 2341 2343 O
subject 10 17 2344 2351 O
's 17 19 2351 2353 O
enzalutamide 20 32 2354 2366 B-treatment
start 33 38 2367 2372 O
date 39 43 2373 2377 O
and 44 47 2378 2381 O
baseline 48 56 2382 2390 O
PSA 57 60 2391 2394 O
( 61 62 2395 2396 O
within 62 68 2396 2402 O
28 69 71 2403 2405 B-upper_bound
days 72 76 2406 2410 I-upper_bound
of 77 79 2411 2413 O
starting 80 88 2414 2422 O
) 88 89 2422 2423 O
before 90 96 2424 2430 O
starting 97 105 2431 2439 O
enzalutamide 106 118 2440 2452 O
available 119 128 2453 2462 O

Serious 0 7 2463 2470 O
intercurrent 8 20 2471 2483 B-chronic_disease
infections 21 31 2484 2494 I-chronic_disease
or 32 34 2495 2497 O
non 35 38 2498 2501 B-chronic_disease
- 38 39 2501 2502 I-chronic_disease
malignant 39 48 2502 2511 I-chronic_disease
medical 49 56 2512 2519 I-chronic_disease
illnesses 57 66 2520 2529 I-chronic_disease
that 67 71 2530 2534 O
are 72 75 2535 2538 O
uncontrolled 76 88 2539 2551 O

Subjects 0 8 2552 2560 O
must 9 13 2561 2565 O
be 14 16 2566 2568 O
on 17 19 2569 2571 O
enzalutamide 20 32 2572 2584 B-treatment
for 33 36 2585 2588 O
metastatic 37 47 2589 2599 B-cancer
CRPC 48 52 2600 2604 I-cancer
and 53 56 2605 2608 O
within 57 63 2609 2615 O
the 64 67 2616 2619 O
first 68 73 2620 2625 O
12 74 76 2626 2628 B-lower_bound
weeks 77 82 2629 2634 I-lower_bound
of 83 85 2635 2637 O
enzalutamide 86 98 2638 2650 O
at 99 101 2651 2653 O
160mg 102 107 2654 2659 O
/ 107 108 2659 2660 O
day 108 111 2660 2663 O

Therapy 0 7 2664 2671 B-treatment
with 8 12 2672 2676 I-treatment
other 13 18 2677 2682 I-treatment
hormonal 19 27 2683 2691 I-treatment
therapy 28 35 2692 2699 I-treatment
, 35 36 2699 2700 O
including 37 46 2701 2710 O
any 47 50 2711 2714 O
dose 51 55 2715 2719 O
of 56 58 2720 2722 O
megestrol 59 68 2723 2732 B-treatment
acetate 69 76 2733 2740 I-treatment
( 77 78 2741 2742 I-treatment
Megace 78 84 2742 2748 I-treatment
) 84 85 2748 2749 I-treatment
, 85 86 2749 2750 O
finasteride 87 98 2751 2762 B-treatment
( 99 100 2763 2764 I-treatment
Proscar 100 107 2764 2771 I-treatment
) 107 108 2771 2772 I-treatment
, 108 109 2772 2773 O
dutasteride 110 121 2774 2785 B-treatment
( 122 123 2786 2787 I-treatment
Avodart 123 130 2787 2794 I-treatment
) 130 131 2794 2795 I-treatment
, 131 132 2795 2796 O
or 133 135 2797 2799 O
any 136 139 2800 2803 O
herbal 140 146 2804 2810 O
product 147 154 2811 2818 O
known 155 160 2819 2824 O
to 161 163 2825 2827 O
decrease 164 172 2828 2836 O
PSA 173 176 2837 2840 B-clinical_variable
levels 177 183 2841 2847 I-clinical_variable
( 184 185 2848 2849 O
e.g. 185 189 2849 2853 O
, 189 190 2853 2854 O
saw 191 194 2855 2858 O
palmetto 195 203 2859 2867 O
and 204 207 2868 2871 O
PC 208 210 2872 2874 B-treatment
- 210 211 2874 2875 I-treatment
SPES 211 215 2875 2879 I-treatment
) 215 216 2879 2880 O
, 216 217 2880 2881 O
or 218 220 2882 2884 O
any 221 224 2885 2888 O
systemic 225 233 2889 2897 B-treatment
corticosteroid 234 248 2898 2912 I-treatment
within 249 255 2913 2919 O
2 256 257 2920 2921 B-upper_bound
weeks 258 263 2922 2927 I-upper_bound
prior 264 269 2928 2933 I-upper_bound
to 270 272 2934 2936 O
first 273 278 2937 2942 O
dose 279 283 2943 2947 O
of 284 286 2948 2950 O
study 287 292 2951 2956 B-treatment
drug 293 297 2957 2961 I-treatment

Total 0 5 2962 2967 B-clinical_variable
bilirubin 6 15 2968 2977 I-clinical_variable
= 16 17 2978 2979 O
< 17 18 2979 2980 O
1.5 19 22 2981 2984 B-upper_bound
x 23 24 2985 2986 I-upper_bound
the 25 28 2987 2990 I-upper_bound
upper 29 34 2991 2996 I-upper_bound
limit 35 40 2997 3002 I-upper_bound
of 41 43 3003 3005 I-upper_bound
normal 44 50 3006 3012 I-upper_bound

a 0 1 3013 3014 O
minimum 2 9 3015 3022 O
washout 10 17 3023 3030 O
of 18 20 3031 3033 O
28 21 23 3034 3036 B-lower_bound
days 24 28 3037 3041 I-lower_bound
for 29 32 3042 3045 O
any 33 36 3046 3049 O
other 37 42 3050 3055 O
anticancer 43 53 3056 3066 B-treatment
therapy 54 61 3067 3074 I-treatment
prior 62 67 3075 3080 I-treatment
to 68 70 3081 3083 I-treatment
first 71 76 3084 3089 I-treatment
dose 77 81 3090 3094 I-treatment
of 82 84 3095 3097 I-treatment
study 85 90 3098 3103 I-treatment
drug 91 95 3104 3108 I-treatment
is 96 98 3109 3111 O
required 99 107 3112 3120 O
( 108 109 3121 3122 O
only 109 113 3122 3126 O
applicable 114 124 3127 3137 O
for 125 128 3138 3141 O
phase 129 134 3142 3147 O
I 135 136 3148 3149 O
) 136 137 3149 3150 O

